Distributor inventory | Tablet
Vildagliptin + Metformin (strengths unknown)
Treatment of type 2 diabetes mellitus to improve glycaemic control along with diet and exercise.
Vildagliptin is a DPP-4 inhibitor that increases incretin levels, enhancing insulin release and reducing glucagon secretion in a glucose-dependent manner. Metformin decreases hepatic glucose production and improves insulin sensitivity, lowering blood glucose levels.
Take by mouth as prescribed by a doctor, usually with meals to reduce stomach upset. Swallow tablet whole with water; do not crush/chew unless advised. Regularly monitor blood glucose and follow diet/exercise advice.
Common side effects of VILDAGLIP M TAB may include:
Type 1 diabetes and diabetic ketoacidosis: not indicated. Metformin can rarely cause lactic acidosis—risk increases with kidney impairment, dehydration, severe infection, hypoxia/heart failure, excessive alcohol use; assess renal function before and during therapy. Vildagliptin may affect liver enzymes—periodic liver function tests recommended; stop if jaundice or significant LFT rise. Use caution in elderly and in renal/hepatic impairment; dose adjustments may be required. Temporarily stop metformin around iodinated contrast procedures and major surgery as advised by doctor. Watch for symptoms of pancreatitis (severe abdominal pain) and severe allergic reactions; seek medical help.
